Search results
Added:
1 year ago
ESC Congress 24 – Join Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) for an insightful series of wrap-ups from the ESC Congress 2024 in London.Trials covered in detail include:FINEARTS-HFMRAs in Heart FailureSENIOR RITAEARTH-STEMISCOFFAVATARWatch the Day 1 and Day 2 ESC 24 wrap-ups from Dr Alasnag and Dr Al-Shaibi here.Recorded on-site at the ESC Congress…
View more
Added:
2 weeks ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
ESC 24: MRAs in HF
Added:
1 year ago
Video
Added:
10 months ago
ESC HF 25 - TITRATE-HF shows 65% of patients with de novo heart failure receive guideline recommended medical therapy at 6 months in the Netherlands.Dr Jasper Brugts (Erasmus University Medical Centre, NL) joins us to discuss the outcomes from the TITRATE-HF study, which investigated adherence to the 2021 ESC guideline reccommendations for patients with heart failure with reduced ejecton fraction…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Gerasimos Filippatos and Prof Muthiah Vaduganathan explore the evolving role of non-steroidal MRAs in heart failure management.
View more
Added:
10 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
Added:
5 months ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation…
View more
Added:
7 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient…
View more
Added:
1 year ago
ESC Congress 24 – Day 1 of the ESC Congress 2024 was filled with excitement as new clinical practice guidelines were unveiled, along with several highly anticipated Hot Line trials.Interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) are concluding the first day by providing practical summaries of the key guidelines and offering critical insights…
View more